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Objectives: We set forth to estimate the number of those with Parkinson’s disease
(PD) in Hungary, a country with a single-payer health insurance system covering 10
million inhabitants.
Methods: We analyzed all hospital and outpatient reports from neurological services
and pharmacy reports of prescription refills. We cross-checked clinically administered
diagnosis of PD with prescription refills of antiparkinsonian medications using record
linkage. We used the ICD-10 code of G20 in any diagnostic category to find all cases with
possible PD. For case certification those patients were considered to have PD who were
recorded with G20 code in at least 2 calendar years. For a more conservative estimation
we determined the number of those who also refilled antiparkinsonian medication.
Results: Between 2010 and 2012 there were 46,383 subjects with certified PD by
clinical criteria. Crude and age-standardized incidence were 49/100,000/year (95% CI:
45–53), and 56/100,000/year (95% CI: 51–60). Crude and age standardized prevalence
rates were 404/100,000 (95% CI: 392–416) and 471/100,000 (95% CI: 456–485). Of all
clinically certified PD patients 72% refilled antiparkinsonian medications.
Discussion: The incidence and prevalence of PD in Hungary is higher than
earlier estimates, which should be considered in organizing healthcare services for
this patient group.
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INTRODUCTION
Parkinson’s disease (PD) is an increasing social and economic
burden worldwide, reducing the quality of life of patients,
being one of the leading causes of neurological disability in the
adult population and being associated with large direct costs to
society (1, 2).
Incidence and prevalence rates of PD vary greatly (3–5).
Observed variations may result from different epidemiologic
methods used, but might also be a consequence of environmental
or genetic factors, differences in age, sex or ethnicity distributions
of the study populations. Global estimates of PD prevalence is
projected to increase dramatically in the upcoming years (6),
therefore there is a growing need to continuously monitor the
incidence and prevalence of the disease.
Generally there are twomain designs for frequency estimation
of PD: case finding studies, in which hospital, general practice
or pharmacy records are searched for diagnosed cases, often in
combination; and door-to-door surveys in which the studied
population is screened for the presence of the disease using the
same, standardized diagnostic criteria. The most reliable method
is a door-to-door survey, however it requires greater effort and
expense than case finding studies (7, 8).
Patients with particularmedical conditions are often identified
from healthcare administrative databases using the International
Classification of Diseases (ICD-9, ICD-10) or pharmacy
records. Such databases offer valuable information for health
economic analyses, healthcare planning, and to a specific degree
epidemiological investigations. Countries with a single-payer
state health insurance system with full coverage of the total
population have the possibility of epidemiological analyses at
a nationwide level. In such analyses, the accuracy of case
definitions needs to be taken into account (9).
Pharmacy data on the other hand are reliable sources of true
drug exposure (10). As for PD, antiparkinsonian drugs (APDs)
are reliable markers in pharmacy records to monitor the presence
of the disease (11).
Thus, identifying a population of patients with PD with
appropriate algorithms used from healthcare administrative
databases and pharmacy data is a potentially practical,
inexpensive strategy to develop large population based
epidemiologic and health service studies (12, 13).
Hungary is a country with 10 million inhabitants and a
single-payer state health insurance system covering the whole
population. Since 1996 patients have been identified in this
system by a 9-digit unique personal code number. This personal
identifier is used in all healthcare services including hospital care,
outpatient specialist care, general practice and pharmacy records.
Previous estimates three decades ago based on door-to-door
survey in a district of the capital city estimated that around 12,300
people may live with PD in Hungary (14), and a European review
reported 21 thousand people in Hungary with PD (15). However,
epidemiological statistics of PD in the region are outdated and
need revision.
In the present study, we calculated the incidence and
prevalence rates of PD in Hungary and we cross checked the
physician administered diagnosis of PD (ICD-10, code G20) by
pharmacy refills of APDs among the total Hungarian population
on an individual level using record linkage.
MATERIALS AND METHODS
In the framework of the Hungarian National Brain Research
Program theNEUROHUN2004–2017 database was created from
medical and medication reports submitted for reimbursement
purposes (16). In the present case PD was assessed using the
database of the National Health Insurance Fund from neurology
departments of all hospitals, neurology outpatient services and
pharmacies throughout Hungary. The original patient identifier
codes were anonymized and encrypted identifiers were used.
The database from hospitals and outpatient services contains
information covering a 10-years period between 2004 and 2013
while pharmacy data are available from 2010. All personal data
protection regulations were followed, and the Ethics Committee
of Semmelweis University, Budapest, Hungary approved the
study (Approval No: SE TUKEB 88/2015).
There are two independent databases that we linked: the
database of the neurological patient care system, and the
pharmacy database of medication refills. Record linkage between
the clinical and pharmacy databases was possible by applying the
encrypted individual identifier.
The study was divided in four phases. Case identification
in the first phase was followed by 3 steps of case certification.
For case identification, all individuals were selected from the
neurological care system covering 10 years (2004–2013), who
used either the inpatient or the outpatient neurological service
at least once during this period and had a primary or secondary
diagnosis of PD (ICD-10, G20).
In the second phase, case certification was performed in the
clinical database. The following criteria had to be fulfilled for a
patient to be considered to have PD in the year of evaluation:
(1.) to receive G20 diagnosis in the neurology care system in
at least 2 years during the 10-year period regardless of the
diagnosis type (i.e., primary/admitting diagnosis or secondary
diagnosis) and
(2.) to be alive at least 1 day in the year of evaluation.
We calculated crude and age-standardized incidence and
prevalence rates of PD in Hungary for each year of the period
2010–2012. The rates were calculated on the data of the first
diagnosis. As for the clinically certain PD diagnosis we required
the appearance of the G20 code in the patient records at least in
2 years, we could not estimate incidence for the last year of the
database i.e., for 2013.
In the third phase, validation of the clinical diagnosis criteria
of PD on a smaller subsample was performed. Firstly, we made
an IT validation of data by cross-checking the database of the
national neurological patient care system (NEUROHUN) and
the local integrated hospital healthcare IT system (MedSol) of
Semmelweis University, Budapest and vice versa, by choosing a
2 months period for examination: November–December, 2012.
First, we identified all patients at our department from the
hospital records (MedSol) who were treated with an ICD-10 code
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of G20 either in the inpatient or the outpatient setting. Using the
year of birth, the postal code of the residence, the gender, the
admission and discharge dates we checked if these patients do
or do not appear in the large database (NEUROHUN). Second,
from the large database we identified those who appeared at least
in 2 years of the study with G20 diagnosis, and one of these
appearances occurred in the period of November-December 2012
at our department. We checked if these patients can be found in
the local hospital records. Finally, in the same period we retrieved
the individual patient healthcare documents of all inpatients (N
= 31) and 19 consecutive outpatients with a clinical diagnosis
of PD, checked if they appear at least in 2 years with G20
diagnosis code in the large database and we made sure that
PD diagnosis is accurate and clinically supported based on final
hospital discharge reports.
In the fourth phase, to achieve a more conservative case
certification, we counted those who fulfill the clinical diagnosis
criteria of PD and also refilled an APD prescription in the
year of interest. APDs are coded N04 in accordance with the
Anatomical Therapeutic Chemical Classification (ATC) system.
N04A-anticholinergic agents as well as N04B-dopaminergic
agents were included. Our analysis could evaluate prescriptions
of N04 ATC drugs refilled at pharmacies, but had no access to
inpatient medication use in hospitals. For this analysis first we
identified all patients with any kind of diagnosis who refilled an
APD between 2010 and 2012. Afterwards, among these patients,
using record linkage we identified those individuals who had a
PD according to our clinical criteria. This way we cross-checked
and validated the clinically administered diagnosis of PD by
pharmacy refills of APD of the same patient. The requirement
of ADP refill in a certain year for case certification results in
underestimating the total number of PD patients, by excluding
those who still live but do not refill an APD in that certain year.
The rate of APD use in PD patients was calculated in two ways
to find the minimum and maximum potential values:




where the nominator is the number of PD patients where our
clinical criteria is met and refilled at least once an N04 ATC
medication, and the denominator is the number of patients with
PD who are alive in the year given and meet our clinical criteria.




where the nominator is the number of PD patients where our
clinical criteria is met and refilled at least once an N04 ATC
medication, and the denominator is the number of patients with
PD who are not only alive but also presented at a neurology
service in the given year.
Data extraction was performed by a research assistant
IT specialist, with several years of experience in reviewing
medical records of patients with neurological conditions.
Results of individual searches in the database were
exported to excel files, which were used for the custom
query for the final analysis of PD patients. The research
team was not blinded to the presence or absence of G20
or other ICD-10 codes either in the clinical or in the
pharmacy data.
Statistical Analysis
The crude incidence and prevalence rates were standardized
to the European standard population of 2013 with 95%
confidence intervals (CI 95%) using a binominal distribution
(17). Calculating incidence and prevalence we considered those
who have PD who fulfill our diagnostic criteria (received G20
diagnoses in at least 2 years).
RESULTS
Estimating the Number of Possible PD
Patients Over 10 Years
Out of the 10 million inhabitants of Hungary, 2.9 million people
used at least once an inpatient or outpatient neurological service
in the 10-year period of 2004–2013. During this time there were
overall 96,874 patients admitted to hospitals or had outpatient
visits at a neurological specialist care at least once with PD,
ICD-10 code G20, as a primary or secondary diagnosis. Patients
with parkinsonism (PKM, only G21–26 diagnoses without any
appearance with G20) are not included in this number. Of
the 96,874 patients with ICD-10 code G20, as a primary or
secondary diagnosis, 60,039 patients were assigned only G20
diagnosis code, whereas 36,835 had at least one G21-26 diagnosis
as well in addition to the G20 code over this 10-year period.
During these 10 years 62,108 patients were registered with
any of the G21-26 diagnoses without any appearance with
G20 code.
TABLE 1 | Number of inpatient record appearances in the hospital IT system
(MedSol), the large national database (NEUROHUN) and vice-versa.
Database MedSol → NEUROHUN NEUROHUN → MedSol
Inpatient appearance 60 → 59 31 → 31
Correspondence 98.3% 100%
TABLE 2 | Number of outpatient record appearances in the hospital IT system
(MedSol), the large national database (NEUROHUN) and vice-versa.
Database MedSol → NEUROHUN NEUROHUN → MedSol
Outpatient appearance 224 → 223 224 → 224
Correspondence 99% 100%
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Validating the Clinical Diagnosis Criteria of
PD on a Smaller Subsample
For comparing inpatient and outpatient records in the hospital IT
system (MedSol) and the large national database (NEUROHUN)
we found the following (Tables 1, 2):
- out of 60 inpatients with G20 in any diagnosis position in the
hospital records 59 appeared also in the national database. The
one missing patient from the national database was due to a
reporting error from the hospital.
- all of the 31 inpatients in the national database with G20
appearing at least in 2 years in the national database with one
of these appearances in the period of Nov.–Dec. 2012 were
present in the local hospital records.
- out of 224 outpatients with G20 in the hospital records 223
appeared in the national database. The onemissing patient had
no patient ID in the hospital records.
- all of the 224 outpatients with G20 appearing at least in 2 years
in the national database with one of these appearances in the
period of Nov.–Dec. 2012 were present in the hospital records.
When comparing medical documents to the national
database, starting from 01 November 2012 until 31 December
2012 we examined final hospital discharge reports from MedSol
of the 31 inpatients and consecutive 19 outpatients to reach
total number of 50 patients, who appeared in NEUROHUN
with 2-year G20 criteria. We found that out of 31 inpatients
26 (84%) had clinically supported PD. The other 5 patients
had a final clinical diagnosis of as follows: multiple system
atrophy (MSA) in one case, progressive supranuclear palsy
(PSP) in 2 cases and in 2 cases other not defined secondary
parkinsonian syndrome. Out of 19 outpatients 18 (94%) had
clinically supported PD. One patient had other not defined
secondary parkinsonian syndrome.
Estimating the Number of Patients With
Clinically Consistent PD Diagnosis for the
Period of 2010–2012
Overall 46,383patients fulfilled our criteria for PD diagnosis
between 2010 and 2012, i.e., they were registered in the
neurological inpatient or outpatient system with G20 diagnosis
at least twice and at least in 2 years of the study period. The
diagnosis of PD was confirmed at least once by a neurology
specialist in 43,009 cases (92%). Table 3 shows all the estimated
crude and age standardized incidence and prevalence rates
per year.
For the 3 years the mean crude incidence rate was
49/100,000/year (95% CI: 45–53), whereas the age standardized
incidence was 56/100,000/year (95% CI: 51–60). Crude and age
standardized mean prevalence rates were 404/100,000 (95% CI:
392–416) and 471/100,000 (95% CI: 456–485), respectively.
The crude rates of incidence and prevalence by 5-year age
categories and by gender are shown in Figures 1A,B.
The male to female ratio of prevalence and incidence showed
male dominance until 70 years of age after which female PD
patients were more frequent.
Linking the Clinically Consistent PD Cases
With APD Medication Refill
The number of patients who refilled annually N04 ATC
prescriptions in the pharmacy database were 48,857, 49,113 and
49,041 in 2010, 2011, and 2012, respectively. The distribution
of different diagnosis types for APD prescriptions each year are
presented in Figure 2.
In the same 3 years the number of clinically consistent PD
patients were 39,355, 40,608 and 41,382. The number of clinically
consistent PD patients who also refilled APD medication was
28,541, 29,735, and 29,667 in these 3 years. The refill rate among
those PD patients who also appeared at a neurology service in the
same year was 0.80, whereas the refill rate of all living PD patients
was 0.72.
DISCUSSION
In the present study our aim was to estimate the number
of those with PD in Hungary and to validate prevalence
and incidence rates by comparing two independent national
healthcare databases. We found that incidence and prevalence
estimates of PD are considerably higher than previous reports.
A door-to-door survey in a district of Budapest performed 3
decades ago estimated an age standardized PD prevalence of
123.1 per 100,000 and age standardized incidence of 9.1 per
100,000 inhabitants per year (17). A European survey 20 years
later gave higher numbers, suggesting 21.6 thousand PD patients
in Hungary. We found even higher numbers, suggesting that
in the years 2010–2012 in Hungary there are around 40,000
patients with PD. If we consider only those 72% who refill APD
medication, the number is still considerably higher than previous
estimates. This increase in incidence and prevalence values can
be explained by the difference in the epidemiologic method used
(more thorough and nationwide case identification) and by the
growing frequency of PD recognition and patient admission to
neurological services over the years.
The number of patients with physician-assigned PD diagnosis
is confirmed by pharmacy refills of disease specific medications
(N04 ATC) in overall 72% of the cases. The refill rate is higher
(80%) among PD patients who receive regular neurological
care. APDs in Hungary are used for PKM as well (ICD-10
diagnosis codes: G21–G26) in 23–24% of all the APD refills
(Figure 2). Similarly to our findings, a report from Italy in 1998
(18) assumed that 75.2% of the total levodopa prescriptions
were for patients with PD. A study with similar population-
level case ascertainment methods like our design reported that
the proportions of those with a levodopa prescription for PD
diagnosis ranged from 39 to 66% (19). In Singapore 92.3% of PD
patients were receiving levodopa (20). The 72% rate of APD refill
in Hungary includes not only levodopa, but all N04 medications,
like DOPA agonists as well.
A study from British Columbia, based on a prescription
database with 97% coverage estimated crude PD prevalence
rates ranging between 109 and 144 per 100,000 inhabitants
(21). From the same region, a historical cohort study using
administrative databases assessed the age-specific incidence of
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TABLE 3 | Incidence (new patients per 100,000 inhabitants/year) and prevalence (number of patients per 100,000 inhabitants) of PD in Hungary between 2010 and 2012.
Year Crude incidence Crude prevalence Standardized incidence* Standardized prevalence*
2010 53 394 59 458
2011 50 406 57 473
2012 46 414 52 483
95% CI overall for 3 years 45–53 392–416 51–60 456–485
*Age standardization was performed using the 2013 European standard population (17).
FIGURE 1 | (A) Crude incidence of PD in Hungary between 2010 and 2012 (per 100,000/year) by 5 year age categories and gender. (B) Crude prevalence of PD in
Hungary between 2010 and 2012 (per 100,000) by 5 year age categories and gender.
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FIGURE 2 | Refill of N04 ATC drugs: with G20 diagnosis, with G21–26 diagnosis and with other diagnosis codes between 2010 and 2012.
PD for persons 65 years or older, and found that the crude
annual incidence rate was 252 per 100,000 person-years (22).
A nationwide pharmacoepidemiological study conducted in
Denmark using a drug tracer methodology from a national
prescription database showed an age standardized prevalence
rate for APD purchase of 164 persons per 100,000 and an
incidence rate of 55 persons per 100,000 inhabitants/year
concluding that prescriptions overestimated PD prevalence (23).
In our study the majority of APDs were prescribed for PD, a
quarter for PKM and a few cases for other diagnoses.
Estimating rates of PD in Israel, based on prescription
database with 25% coverage of the population showed an
incidence rate of 33 per 100,000/year and a prevalence rate which
increased from 170 to 256 per 1000,000 over the years, indicating
a burden of PD in Israel higher than previously assumed (24).We
have also come to a similar conclusion.
In Hungary it was previously demonstrated that
hospital discharge reports accurately identify patients with
cerebrovascular diseases, if primary as well as secondary
diagnoses are considered simultaneously during data analysis
(25). As hospital reimbursement is based on the DRG system
in Hungary, for some PD patients the primary diagnosis
in the discharge report may be other than PD for financial
considerations. However, PD also appears in the discharge report
of these patients coded as a secondary diagnosis. Therefore, if
hospital discharge reports are used to identify patients with PD,
all discharge diagnosis categories, primary as well as secondary,
should be considered.
Differentiating PD, especially at disease onset, from PKM
is often difficult and challenging. Furthermore, PKMs are also
frequently treated as PD due to responsiveness to dopaminergic
therapy in some cases. Since society, patients, relatives and the
health care system are similarly affected with PD and PKM, their
merger may be justified from the disease burden perspective.
Although administrative data are a convenient and a relevant
source for studying specific patient populations, it is a challenge
to create a valid approach for correctly identifying patients with
PD or PKMs. A report from 2010 found that the ICD-9 code
for PKM has good sensitivity (75%) and excellent specificity
(99.1%) (26), however a systematic review indicated that for
PD/PKM the sensitivity of ICD codes was 18.7–100% and the
specificity was between 0 and 99.9% (9). In a study about
accuracy estimates, the authors concluded that administrative
data were limited in the ability to identify PKM and distinguish
between PD and PKM, however the addition of pharmacy data
improved sensitivity. The authors also recommended identifying
cases from multiple administrative databases and the use of
algorithms to distinguish between the categories of PKM (13).
Additionally, identifying a population of patients with PD
from administrative databases represents a complicated issue
for several other reasons which affect our study as well: (1)
PD is a clinical diagnosis and it is definitively identified only
by brain pathological findings (27), therefore the degree of
clinical uncertainty always remains present. However, accuracy
of the clinical diagnosis is likely to become more assured over
time as clinical data accumulates therefore we used the 2 year
diagnostic criteria; (2) PD diagnoses used in the study are not
made by direct contact with the patients but by reliability on
physicians/specialists reports prepared essentially for financial
purposes; (3) As our results show, a greater number of persons are
using N04 ATC medications than the estimated figure of persons
with PD. The differences may partly be explained by the fact that
N04 ATC drugs are not specific and unique medications for PD
as they are also used for other conditions (e.g., drug-induced
PKM, restless legs syndrome, tremor disorder, dopa-responsive
dystonia - codes: G21–26) often less regularly and at lower doses;
(4) the diagnosis is specified wrong on the prescription for a N04
ATC medication.
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There are certain strengths of this study. First, we could
analyze the database of a several years’ time period with 100%
coverage of the country with 10 million inhabitants, making
this the largest Hungarian epidemiological study of PD. Second,
while chronic diseases are often under-reported during hospital
admissions where the condition may not be the primary cause of
admission (28), the use of all categories of discharge diagnoses
increases the efficacy of case identification. Third, by considering
PD in all diagnostic categories of the discharge reports, the bias
caused by financial considerations in reporting was diminished.
Fourth, by cross-checking 2 independent databases—the clinical
and the pharmacy repots—we could validate the accuracy of the
diagnosis of PD.
This study also has several limitations. First, diagnostic
accuracy may be limited by the lack of a direct individual
clinical case certification by physical examination and individual
chart review. Second, an overestimation of the number of PD
patients may result from the application of PD diagnosis code
(G20) or APD-based treatment (N04 ATC) for those who
indeed had PKM. Third, underestimation of the number of
those with PD may have occurred by exclusion of patients
with clinical or pharmacy codes of PKM (G21–G26) who might
indeed had PD. The possibility of misclassification error should
be considered as an important source of research bias using
health administrative databases and threatens the validity of
study results (29). Additionally, patients not presenting in the
neurological care system, undiagnosed patients, patients who
have not yet been commenced on antiparkinsonian therapy,
or those who do not refill the prescribed medication due
to disadvantaged socioeconomic conditions result in further
underestimation of the number of patients with PD.
In conclusion, the NEUROHUN database with proper
case identification and case certification methodology can
be appropriate to evaluate clinical, epidemiological, and
organizational features of PD in Hungary. The higher incidence
and prevalence values than previously estimated, reflect the
growing burden of PD on the Hungarian health care system. The
database has the potential to estimate quality of care, cost of care,
follow-up and prevalence of PD or other specific neurological
conditions in Hungary.
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